ReviewGlomerular diseases2022
IgA Nephropathy: A Chinese Perspective.
Review in Glomerular diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Sexually dimorphic response to tobacco in the development of chronic kidney disease: a systematic review.BMC nephrology · 2024Pooled it
- Kidney biopsy in patients with small kidneys: diagnostic yield and treatment modification in a retrospective cohort study.Renal failure · 2026Article
- Association of Complement Genetics with Outcomes in IgA Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Unveiling the immune landscape and microenvironmental architecture of IgA nephropathy using single-cell imaging mass cytometry.Clinical & translational immunology · 2026Article
- Alport syndrome complicated with IgA nephropathy: a case report.Frontiers in medicine · 2026Article
- Renal outcomes and predictive value of dyslipidemia in patients with IgA nephropathy: a retrospective cohort study.Frontiers in medicine · 2026Article
- Identification of key genes related to arginine metabolism in immunoglobulin A nephropathy through the combination of scRNA-seq and bulk RNA-seq data.Frontiers in immunology · 2026Article
- Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections.BMC nephrology · 2025Article
- Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients.Scientific reports · 2025Article
- Immunoglobulin A Nephropathy: A Review.The Permanente journal · 2024Review
- Causal role of immune cells in IgA nephropathy: a mendelian randomization study.Renal failure · 2024Article
- Genetics of IgA nephrology: risks, mechanisms, and therapeutic targets.Pediatric nephrology (Berlin, Germany) · 2024Review
- Mortality in IgA Nephropathy: A Long-Term Follow-Up of an Eastern European Cohort.Medicina (Kaunas, Lithuania) · 2024Article
- A preliminary probabilistic nomogram model for predicting renal arteriolar damage in IgA nephropathy from clinical parameters.Frontiers in immunology · 2024Article
- Understanding patient needs and predicting outcomes in IgA nephropathy using data analytics and artificial intelligence: a narrative review.Clinical kidney journal · 2023Review
- NovelWorld journal of clinical cases · 2023Article
- IgA Nephropathy: A Tale of 3 Continents.Glomerular diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and remains a leading cause of chronic kidney disease and end-stage renal disease. The disease prevalence, clinical and pathological phenotypes, the underlying pathogenic molecular mechanisms, and the response to treatments are highly heterogeneous in different ethnic populations, which raise the concern that IgAN may differ across different parts of the world. Summary: From a Chinese perspective, we stated the disease burden of IgAN, summarized genome-wide association studies and research into pathological molecules, and compared them with findings based on other populations. The emerging biomarkers, indigenous clinical trials, and major challenges for Chinese researchers and nephrologists in studying IgAN are also discussed. Key Messages: In this review, we described a higher risk of major susceptible loci in mucosal immunity, IgA production, and complement activation pathways in Chinese patients with IgAN. With our understanding of the pathogenesis of IgAN, novel biomarkers are emerging. Although there are challenges for conducting high-quality clinical trials in China, it is still feasible to conduct innovative and well-designed studies of IgAN. In the future, international collaborations on research infrastructure would be helpful to advance clinical and basic research in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.